Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib

Summary

The purpose of this study is to evaluate the clinical benefit rate at 12 weeks from the addition of pazopanib to a non-steroidal aromatase inhibitor (NSAI) (letrozole or anastrozole) in patients with hormone receptor positive advanced breast cancer progressing on the same NSAI hormone therapy.

Timeline

Start

2012-04-27

Primary completion

2015-12-07

Completion

2019-10-02

Drugs

Indications